Bulk drug exemption under Notification No. 8/96-C.E. extends to products meeting alternative statutory standards, not just pharmacopoeial listings.

A bulk drug qualifies for concessional duty under Notification No. 8/96-C.E. when it conforms to the pharmacopoeial standards or the alternative standards specified in the Second Schedule to the Drugs and Cosmetics Act, 1940. Eligibility cannot be denied merely because the product is not listed in a pharmacopoeia if it satisfies the prescribed statutory standards and has been accepted by the drug control authorities on that basis. The notification was read as covering either category of standards, so compliance with the alternative standards was sufficient for concessional treatment.

---

---

Issues: Whether a bulk drug is entitled to concessional duty under Notification No. 8/96-C.E. when it conforms to standards specified in the Second Schedule to the Drugs and Cosmetics Act, 1940 even if it is not listed in a pharmacopoeia.

Analysis: The notification defined bulk drugs as pharmaceutical, chemical, biological or plant products conforming to pharmacopoeial standards or other standards specified in the Second Schedule to the Drugs and Cosmetics Act, 1940. The departmental clarification also accepted that the notification covered products meeting either category of standards. The product in question had been permitted for manufacture by the drug control authorities on the basis that it satisfied the relevant standards, and therefore the refusal of the concessional rate merely because it was not then found in a pharmacopoeia was unsustainable.

Conclusion: The product qualified as a bulk drug for the purposes of Notification No. 8/96-C.E. and the denial of concessional duty was unjustified, in favour of the assessee.

Final Conclusion: The appeal failed and the exemption benefit was upheld on the basis that compliance with the prescribed statutory standards was sufficient for concessional treatment.

Ratio Decidendi: Where an exemption notification defines bulk drugs by reference to pharmacopoeial or other prescribed standards, eligibility cannot be denied merely because the product is not listed in a pharmacopoeia if it satisfies the alternative statutory standards.

---